

Gianfranco Cicoria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/616074/publications.pdf>

Version: 2024-02-01

53
papers

942
citations

471509

17
h-index

501196

28
g-index

54
all docs

54
docs citations

54
times ranked

1417
citing authors

#	ARTICLE	IF	CITATIONS
1	An HPLC and UHPLC-HRMS approach to study PSMA-11 instability in aqueous solution. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 14.	3.9	5
2	In vitro thrombogenicity of drug-eluting and bare metal stents. Thrombosis Research, 2020, 185, 43-48.	1.7	5
3	Radiotherapy-induced malfunctions of cardiac implantable electronic devices in cancer patients. Internal and Emergency Medicine, 2020, 15, 967-973.	2.0	9
4	Cyclotron solid targets preparation for medical radionuclides production in the framework of LARAMED project. Journal of Physics: Conference Series, 2020, 1548, 012022.	0.4	7
5	Activation studies for the decommissioning of PET cyclotron bunkers by means of Monte Carlo simulations. Radiation Physics and Chemistry, 2020, 174, 108966.	2.8	13
6	Production of ⁶⁷ Cu by enriched ⁷⁰ Zn targets: first measurements of formation cross sections of ⁶⁷ Cu, ⁶⁴ Cu, ⁶⁷ Ga, ⁶⁶ Ga, ^{69m} Zn and ⁶⁵ Zn in interactions of ⁷⁰ Zn with protons above 45 MeV. Radiochimica Acta, 2020, 108, 593-602.	1.2	28
7	A bis(thiosemicarbazone) bifunctional chelating agent for nitrido-technetium-99m and copper-64 based radiopharmaceuticals. Nuclear Medicine and Biology, 2019, 72-73, S28.	0.6	0
8	Activation studies of a PET cyclotron bunker. Radiation Physics and Chemistry, 2019, 161, 48-54.	2.8	12
9	⁶⁴ Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. Scientific Reports, 2019, 9, 3376.	3.3	13
10	Medical Cyclotron Solid Target Preparation by Ultrathick Film Magnetron Sputtering Deposition. Instruments, 2019, 3, 21.	1.8	14
11	Innovative Target for Production of Technetium-99m by Biomedical Cyclotron. Molecules, 2019, 24, 25.	3.8	21
12	Low dose radiation ¹⁸ F-fluoride PET/CT in the assessment of Unilateral Condylar Hyperplasia of the mandible: preliminary results of a single centre experience. European Journal of Hybrid Imaging, 2018, 2, 7.	1.5	7
13	Transglutaminase-mediated conjugation and nitride-technetium-99m labelling of a bis(thiosemicarbazone) bifunctional chelator. Journal of Inorganic Biochemistry, 2018, 183, 18-31.	3.5	10
14	Radioisotopic purity and imaging properties of cyclotron-produced ^{99m} Tc using direct ¹⁰⁰ Mo(<i>p</i> , <i>n</i>) reaction. Physics in Medicine and Biology, 2018, 63, 185021.	3.0	17
15	Production of Ga-68 with a General Electric PETtrace cyclotron by liquid target. Physica Medica, 2018, 55, 116-126.	0.7	29
16	In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticals. Applied Radiation and Isotopes, 2018, 139, 325-331.	1.5	35
17	Modeling of a Cyclotron Target for the Production of ¹¹ C with Geant4. Current Radiopharmaceuticals, 2018, 11, 92-99.	0.8	3
18	Early and delayed evaluation of solid tumours with ⁶⁴ Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Characterization of ^{41}Ar production in air at a PET cyclotron facility. <i>Modern Physics Letters A</i> , 2017, 32, 1740014.	1.2	9
20	Radiation Protection Studies for Medical Particle Accelerators using Fluka Monte Carlo Code. <i>Radiation Protection Dosimetry</i> , 2017, 173, 185-191.	0.8	9
21	Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With ^{64}Cu -ATSM PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, e87-e92.	1.3	32
22	Assessment of the neutron dose field around a biomedical cyclotron: FLUKA simulation and experimental measurements. <i>Physica Medica</i> , 2016, 32, 1602-1608.	0.7	16
23	An innovative gamma-ray spectrometry system using a compact and portable CZT detector for radionuclidic purity tests of PET radiopharmaceuticals. <i>Radiation Effects and Defects in Solids</i> , 2016, 171, 726-735.	1.2	3
24	The concept of minimum detectable activity of radionuclide activity meters and their suitability for routine quality control of radiopharmaceuticals. An experimental study. <i>Applied Radiation and Isotopes</i> , 2016, 113, 22-27.	1.5	4
25	A solvent-extraction module for cyclotron production of high-purity technetium-99m. <i>Applied Radiation and Isotopes</i> , 2016, 118, 302-307.	1.5	29
26	Synthesis and preclinical evaluation of an Al^{18}F radiofluorinated $\text{GLU-UREA-LYS(AHX)-HBED-CC}$ PSMA ligand. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2122-2130.	6.4	42
27	Efficiency calibration of a portable CZT detector for nondestructive activation assessment of a cyclotron bunker. <i>Radiation Effects and Defects in Solids</i> , 2016, 171, 705-713.	1.2	7
28	Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment. <i>Nanomedicine</i> , 2015, 10, 3483-3494.	3.3	57
29	Experimental measurement and Monte Carlo assessment of Argon-41 production in a PET cyclotron facility. <i>Physica Medica</i> , 2015, 31, 991-996.	0.7	10
30	Accurate Monte Carlo modeling of cyclotrons for optimization of shielding and activation calculations in the biomedical field. <i>Radiation Physics and Chemistry</i> , 2015, 116, 231-236.	2.8	23
31	Usefulness of ^{64}Cu -ATSM in Head and Neck Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, e59-e63.	1.3	36
32	Monte Carlo modeling provides accurate calibration factors for radionuclide activity meters. <i>Applied Radiation and Isotopes</i> , 2014, 94, 158-165.	1.5	8
33	Radiation dose around a PET scanner installation: Comparison of Monte Carlo simulations, analytical calculations and experimental results. <i>Physica Medica</i> , 2014, 30, 448-453.	0.7	6
34	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 365-84.	1.0	109
35	Accurate modeling of a DOI capable small animal PET scanner using GATE. <i>Applied Radiation and Isotopes</i> , 2013, 75, 105-114.	1.5	13
36	Use of ^{65}Zn as a tracer for the assessment of purification in the ^{68}Ga -DOTANOC synthesis. <i>Applied Radiation and Isotopes</i> , 2013, 80, 27-31.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Automation synthesis modules review. Applied Radiation and Isotopes, 2013, 76, 38-45.	1.5	50
38	Generator Breakthrough and Radionuclidic Purification in Automated Synthesis of ⁶⁸ Ga-DOTANOC. Current Radiopharmaceuticals, 2013, 6, 72-77.	0.8	15
39	Synthesis of oncological [¹¹ C]radiopharmaceuticals for clinical PET. Nuclear Medicine and Biology, 2012, 39, 447-460.	0.6	24
40	Effective production of ⁶⁵ Zn with a PET cyclotron. Applied Radiation and Isotopes, 2012, 70, 1590-1594.	1.5	6
41	Assessment of internal contamination hazard and fast monitoring for workers involved in maintenance operations on PET cyclotrons. Radiation Protection Dosimetry, 2011, 144, 468-472.	0.8	5
42	Prediction of ⁸⁹ Zr production using the Monte Carlo code FLUKA. Applied Radiation and Isotopes, 2011, 69, 1134-1137.	1.5	32
43	Some experimental studies on ⁸⁹ Zr production. Radiochimica Acta, 2011, 99, 631-634.	1.2	15
44	Experimental monitoring of ozone production in a PET cyclotron facility. Applied Radiation and Isotopes, 2010, 68, 1933-1936.	1.5	3
45	Development of a modular system for the synthesis of PET [¹¹ C]labelled radiopharmaceuticals. Applied Radiation and Isotopes, 2009, 67, 1869-1873.	1.5	12
46	Undesired radionuclides in ¹⁸ F ₂ production by deuterons. Radiation Effects and Defects in Solids, 2009, 164, 336-339.	1.2	2
47	Synthesis and quality control of ⁶⁸ Ga citrate for routine clinical PET. Nuclear Medicine Communications, 2009, 30, 542-545.	1.1	38
48	Acceptance Tests and Quality Control of Ge/ Ga Generators. Current Radiopharmaceuticals, 2009, 2, 165-168.	0.8	3
49	Neutron production in the operation of a 16.5MeV PETtrace cyclotron. Progress in Nuclear Energy, 2008, 50, 939-943.	2.9	16
50	Assessment of radionuclidic impurities in 2-[¹⁸ F]fluoro-2-deoxy-d-glucose ([¹⁸ F]FDG) routine production. Applied Radiation and Isotopes, 2008, 66, 295-302.	1.5	40
51	Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue ⁶⁸ Ga DOTA NOC. Applied Radiation and Isotopes, 2008, 66, 1091-1096.	1.5	16
52	Automated synthesis of [¹¹ C]meta hydroxyephedrine, a PET radiopharmaceutical for studying sympathetic innervation in the heart. , 2008, , .		1
53	Radiation emission dose from patients administered ⁹⁰ Y-labelled radiopharmaceuticals: comparison of experimental measurements versus Monte Carlo simulation. Nuclear Medicine Communications, 2008, 29, 1100-1105.	1.1	11